Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
KYMR Stock Summary
Top 10 Correlated ETFs
KYMR
In the News
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET.
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET.
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, Ph.D., Founder, President and CEO, will provide an overview of the Company's progress and anticipated milestones for 2024.
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.
Soros snaps up tech stocks in Q3, but dumps some of the biggest names, along with Rivian
Soros Fund Management, the investment firm founded by billionaire George Soros, took new positions or bulked up on IPOs and a number of tech names during the third quarter.
Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases
Kymera's KT-474 shows promise in Phase I for HS and AD, balancing clinical potential with financial challenges. Despite revenue decrease, Kymera's strong current ratio and ample cash reserves provide short-term financial stability. Market sentiment is mixed, with high short interest and cautious institutional and insider activities reflecting investor skepticism.
Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Bruce Jacobs - CFO Conference Call Participants Brad Canino - Stifel Gospel M. Enyindah-Asonye - Morgan Stanley Marc Frahm - TD Cowen Eric Joseph - JPMorgan Srikripa Devarakonda - Truist Securities Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Kalpit Patel - B.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, today announced that the Company will participate at the following upcoming investor events:
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
WATERTOWN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, will report third quarter 2023 financial results on November 2, 2023, and will host a conference call at 8:00 a.m. ET that day.
KYMR Financial details
KYMR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.1 | 1.96 | 1.52 | 0.87 | 0 | |
Net income per share | -1.37 | -2.53 | -2.04 | -2.82 | 0 | |
Operating cash flow per share | 0.59 | 5.08 | -2.69 | -2.84 | 0 | |
Free cash flow per share | 0.58 | 4.56 | -2.72 | -2.89 | 0 | |
Cash per share | 3.05 | 17.07 | 9.22 | 7.55 | 0.01 | |
Book value per share | -2.46 | 16.36 | 9.58 | 9.09 | 0.01 | |
Tangible book value per share | -2.46 | 16.36 | 9.58 | 9.09 | 0.01 | |
Share holders equity per share | -2.46 | 16.36 | 9.58 | 9.09 | 0.01 | |
Interest debt per share | 0.7 | 1.04 | 0.38 | 0.32 | 0 | |
Market cap | 1B | 1.08B | 3.05B | 1.35B | 1485.99B | |
Enterprise value | 949.47M | 1.06B | 3.02B | 1.3B | 1485.96B | |
P/E ratio | -24.32 | -24.48 | -31.09 | -8.87 | -10.11K | |
Price to sales ratio | 342.29 | 31.61 | 41.83 | 28.75 | 18.91K | |
POCF ratio | 56.09 | 12.21 | -23.63 | -8.79 | -14.45K | |
PFCF ratio | 57.81 | 13.61 | -23.34 | -8.63 | -10.82K | |
P/B Ratio | -13.5 | 3.79 | 6.63 | 2.75 | 3.76K | |
PTB ratio | -13.5 | 3.79 | 6.63 | 2.75 | 3.76K | |
EV to sales | 323.61 | 31.22 | 41.42 | 27.66 | 18.91K | |
Enterprise value over EBITDA | -23.52 | -23.37 | -30.16 | -8.38 | -10.38K | |
EV to operating cash flow | 53.03 | 12.06 | -23.4 | -8.46 | -14.45K | |
EV to free cash flow | 54.65 | 13.45 | -23.11 | -8.31 | -10.82K | |
Earnings yield | -0.04 | -0.04 | -0.03 | -0.11 | 0 | |
Free cash flow yield | 0.02 | 0.07 | -0.04 | -0.12 | 0 | |
Debt to equity | -0.28 | 0.06 | 0.04 | 0.04 | 0.21 | |
Debt to assets | 0.18 | 0.04 | 0.03 | 0.03 | 0.15 | |
Net debt to EBITDA | 1.36 | 0.29 | 0.3 | 0.33 | 0.18 | |
Current ratio | 2.69 | 2.73 | 5.62 | 8.84 | 4.73 | |
Interest coverage | -917.5 | -402.64 | -574.46 | -916.23 | -844.54 | |
Income quality | -0.43 | -1.93 | 1.29 | 0.99 | 0.7 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.72 | 0.54 | 0.5 | 0.94 | 0.7 | |
Research and developement to revenue | 12.66 | 1.82 | 1.88 | 3.51 | 2.41 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.03 | -0.1 | 0.01 | 0.02 | 0.34 | |
Capex to revenue | -0.18 | -0.27 | -0.02 | -0.06 | -0.44 | |
Capex to depreciation | -0.64 | -5.16 | -0.67 | -0.95 | -9.67 | |
Stock based compensation to revenue | 0.41 | 0.15 | 0.34 | 0.76 | 0.55 | |
Graham number | 8.71 | 30.54 | 20.98 | 23.99 | 0.02 | |
ROIC | 1.32 | -0.14 | -0.2 | -0.3 | -0.33 | |
Return on tangible assets | -0.35 | -0.09 | -0.16 | -0.25 | -0.26 | |
Graham Net | -3.28 | 0.71 | 6.08 | 5.38 | 0 | |
Working capital | 58.28M | 191.72M | 466.57M | 496.23M | 319.63M | |
Tangible asset value | -74.41M | 283.89M | 459.64M | 490.15M | 394.97M | |
Net current asset value | -98.26M | 99.05M | 421.34M | 446.51M | 224.53M | |
Invested capital | -0.28 | 0.06 | 0.04 | 0.04 | 0.21 | |
Average receivables | 74K | 716.5K | 784K | 1.34M | 10.65M | |
Average payables | 2.67M | 3.82M | 4.19M | 4.17M | 5.71M | |
Average inventory | 0 | -81.69M | -86.19M | -10.62M | -6.13M | |
Days sales outstanding | 0 | 15.37 | 0.68 | 19.78 | 87.14 | |
Days payables outstanding | 1.45K | 25.67 | 609.86 | 531.5 | 724.37 | |
Days of inventory on hand | 0 | -960.25 | -1.37K | -1.5K | 0 | |
Receivables turnover | 0 | 23.75 | 539.5 | 18.46 | 4.19 | |
Payables turnover | 0.25 | 14.22 | 0.6 | 0.69 | 0.5 | |
Inventory turnover | 0 | -0.38 | -0.27 | -0.24 | 0 | |
ROE | 0.55 | -0.15 | -0.21 | -0.31 | -0.37 | |
Capex per share | -0.02 | -0.52 | -0.03 | -0.05 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.28 | 0.16 | 0.28 | 0.08 | 0.82 | |
Net income per share | -0.59 | -0.63 | -0.67 | -0.9 | -0.25 | |
Operating cash flow per share | -0.68 | -0.76 | -0.6 | -0.54 | 0.14 | |
Free cash flow per share | -0.69 | -0.82 | -0.79 | -0.68 | -0.06 | |
Cash per share | 7.03 | 6.82 | 6.3 | 6.12 | 6.41 | |
Book value per share | 8.47 | 7.94 | 7.47 | 6.77 | 6.75 | |
Tangible book value per share | 8.47 | 7.94 | 7.47 | 6.77 | 6.75 | |
Share holders equity per share | 8.47 | 7.94 | 7.47 | 6.77 | 6.75 | |
Interest debt per share | 0.3 | 2.26 | 1.29 | 1.38 | 1.45 | |
Market cap | 1.44B | 1.72B | 1.34B | 812.06M | 1.49B | |
Enterprise value | 1.39B | 1.74B | 1.36B | 811.86M | 1.46B | |
P/E ratio | -10.61 | -11.78 | -8.64 | -3.84 | -25.93 | |
Price to sales ratio | 89.53 | 182.13 | 81.2 | 171.76 | 31.12 | |
POCF ratio | -36.55 | -39.21 | -38.03 | -25.66 | 185.2 | |
PFCF ratio | -36.21 | -35.94 | -29.14 | -20.44 | -416.19 | |
P/B Ratio | 2.95 | 3.73 | 3.08 | 2.05 | 3.77 | |
PTB ratio | 2.95 | 3.73 | 3.08 | 2.05 | 3.77 | |
EV to sales | 86.37 | 183.85 | 82.58 | 171.71 | 30.59 | |
Enterprise value over EBITDA | -40.05 | -42.58 | -36.03 | -14.12 | -109.1 | |
EV to operating cash flow | -35.26 | -39.58 | -38.68 | -25.65 | 182.06 | |
EV to free cash flow | -34.93 | -36.27 | -29.63 | -20.44 | -409.13 | |
Earnings yield | -0.02 | -0.02 | -0.03 | -0.07 | -0.01 | |
Free cash flow yield | -0.03 | -0.03 | -0.03 | -0.05 | 0 | |
Debt to equity | 0.04 | 0.28 | 0.17 | 0.2 | 0.21 | |
Debt to assets | 0.03 | 0.21 | 0.13 | 0.15 | 0.15 | |
Net debt to EBITDA | 1.47 | -0.4 | -0.6 | 0 | 1.88 | |
Current ratio | 8.84 | 4.18 | 7.06 | 5.95 | 4.73 | |
Interest coverage | -666.05 | -824.11 | -903.81 | 1.4K | -371.38 | |
Income quality | 1.13 | 1.07 | 0.91 | 0.6 | -0.56 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.72 | 1.33 | 0.86 | 2.99 | 0.3 | |
Research and developement to revenue | 2.67 | 4.46 | 2.77 | 10.18 | 1.11 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.09 | 0.31 | 0.26 | -1.44 | |
Capex to revenue | -0.02 | -0.42 | -0.65 | -1.71 | -0.24 | |
Capex to depreciation | -0.46 | -4.56 | -11.96 | -9.03 | -13.05 | |
Stock based compensation to revenue | 0.55 | 0.99 | 0.68 | 2.47 | 0.23 | |
Graham number | 10.59 | 10.6 | 10.57 | 11.74 | 6.11 | |
ROIC | -0.07 | -0.06 | -0.08 | -0.1 | -0.05 | |
Return on tangible assets | -0.06 | -0.06 | -0.07 | -0.1 | -0.02 | |
Graham Net | 5.01 | 4.13 | 3.84 | 3.49 | 3.56 | |
Working capital | 496.23M | 392.35M | 330.8M | 312.53M | 319.63M | |
Tangible asset value | 490.15M | 462.01M | 435.43M | 395.54M | 394.97M | |
Net current asset value | 446.51M | 363.99M | 238.89M | 218.85M | 224.53M | |
Invested capital | 0.04 | 0.28 | 0.17 | 0.2 | 0.21 | |
Average receivables | 2.71M | 2.93M | 3.72M | 3.95M | 11.27M | |
Average payables | 5.33M | 5.41M | 5.11M | 4.36M | 6.03M | |
Average inventory | -6.13M | -13.46M | -7.34M | 0.5 | 0 | |
Days sales outstanding | 14.15 | 31.57 | 22.47 | 71.92 | 35.26 | |
Days payables outstanding | 476.96 | 648.3 | 374.5 | 497.8 | 736.13 | |
Days of inventory on hand | -1.35K | -1.47K | 0 | 0 | 0 | |
Receivables turnover | 6.36 | 2.85 | 4.01 | 1.25 | 2.55 | |
Payables turnover | 0.19 | 0.14 | 0.24 | 0.18 | 0.12 | |
Inventory turnover | -0.07 | -0.06 | 900K | 0 | 0 | |
ROE | -0.07 | -0.08 | -0.09 | -0.13 | -0.04 | |
Capex per share | -0.01 | -0.07 | -0.18 | -0.14 | -0.2 |
KYMR Frequently Asked Questions
What is Kymera Therapeutics, Inc. stock symbol ?
Kymera Therapeutics, Inc. is a US stock , located in Watertown of Ma and trading under the symbol KYMR
Is Kymera Therapeutics, Inc. buy or a sell ?
11 stock analysts have 11 predictions with a medium analyst target price of $46.93. The lowest prediction is $31 and the highest is $80
What is KYMR stock prediction ?
What is Kymera Therapeutics, Inc. stock quote today ?
Kymera Therapeutics, Inc. stock price is $40.17 today.
Is Kymera Therapeutics, Inc. stock public?
Yes, Kymera Therapeutics, Inc. is a publicly traded company.